Nitroimidazoles as anti-tumor agents.

Abstract

At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.

• Authors: Kai Liu, Hai-Liang Zhu
• Journal: Anti-cancer agents in medicinal chemistry (Anticancer Agents Med Chem) Vol. 11 Issue 7 Pg. 687-91 (Sep 2011) ISSN: 1875-5992 [Electronic] Netherlands
• PMID: 21521156 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Nitroimidazoles
• Prodrugs
• Radiation-Sensitizing Agents
• Oxygen

Topics

• Animals
• Antineoplastic Agents (chemistry, metabolism, pharmacology)
• Biotransformation
• Humans
• Hypoxia (metabolism)
• Neoplasms (drug therapy, pathology, radiotherapy)
• Nitroimidazoles (chemistry, metabolism, pharmacology)
• Oxidation-Reduction
• Oxygen (metabolism)
• Prodrugs (chemistry, metabolism, pharmacology)
• Radiation-Sensitizing Agents (chemistry, metabolism, pharmacology)
• Tumor Cells, Cultured